Recombinant full-length human ROR gamma T protein was used as the immunogen for the ROR gamma antibody.
Retina-associated orphan receptors (RORs) contains three subtypes: RORAlpha, RORBeta, and RORGamma. They are widely distributed in body tissues, and most of them can directly enter the nucleus to regulate the transcription of target genes, thus showing different tissue specificity and participating in different physiological processes. In particular, RORAlpha and RORGamma play an important role in mediating Th17 cell differentiation. RORGamma can be divided into RORGamma1 and RORGamma2 (RORGamma T), which show different tissue specificity. ROR Gamma (T) is expressed only in lymphoid compartment cells, i.e., CD4+CD8+ double positive thymocytes, peripheral Th17 cells, and lymphoid tissue inducer (LTi) cells of lymphoid organs. At present, RORGamma T is considered as a new target for drug development against autoimmune diseases, especially psoriasis. In recent years, RORGamma T small molecule inhibitors have become a hot research field in academia and even international pharmaceutical companies, with great development potential.
